PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND

PRIMETEST II is an interventional study involving low-volume metastatic seminoma. It explores a novel approach using robot-assisted primary retroperitoneal lymph node dissection, aiming to reduce long-term side effects and improve quality of life. By identifying factors predicting cancer recurrence, the study hopes to tailor treatments for better outcomes. The approach could potentially spare patients from chemotherapy induced long-term side effects while maintaining excellent survival rates, presenting a promising shift in testicular cancer care for this specific patient group.

NCT Number	NCT06144736
Lead Sponsor	Heinrich-Heine University, Duesseldorf
Conditions	Seminoma
Enrollment	60 participants
Start Date	2023-08-28
Primary Completion	2026-08-31 (estimated)
Study Completion	2029-08-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-15